241 related articles for article (PubMed ID: 32140784)
1. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
[TBL] [Abstract][Full Text] [Related]
2. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation.
Jiang Y; Tang H; Ma X; Cheng Q; Lin H; Jin X; Zhang Z; Yu W; He S; Kobayashi T; Uehara S; Matsumoto T; Xia W
J Bone Miner Metab; 2019 Nov; 37(6):1036-1047. PubMed ID: 31087185
[TBL] [Abstract][Full Text] [Related]
3. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
Soen S; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Ito M; Nakano T; Hagino H; Hirakawa A; Matsumoto T
J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
[TBL] [Abstract][Full Text] [Related]
4. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
Ringe JD; Faber H; Fahramand P; Schacht E
J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
[TBL] [Abstract][Full Text] [Related]
5. Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis.
Cui L; Xia W; Yu C; Dong S; Pei Y
Arch Osteoporos; 2022 May; 17(1):74. PubMed ID: 35513519
[TBL] [Abstract][Full Text] [Related]
6. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
[TBL] [Abstract][Full Text] [Related]
7. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study.
Matsumoto T; Ito M; Hayashi Y; Hirota T; Tanigawara Y; Sone T; Fukunaga M; Shiraki M; Nakamura T
Bone; 2011 Oct; 49(4):605-12. PubMed ID: 21784190
[TBL] [Abstract][Full Text] [Related]
8. Relationship between the effect of eldecalcitol and serum 25(OH)D level.
Takano T; Kondo S; Saito H; Matsumoto T;
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():124-7. PubMed ID: 24240066
[TBL] [Abstract][Full Text] [Related]
9. Eldecalcitol: newly developed active vitamin D(3) analog for the treatment of osteoporosis.
Hagino H
Expert Opin Pharmacother; 2013 Apr; 14(6):817-25. PubMed ID: 23477453
[TBL] [Abstract][Full Text] [Related]
10. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
11. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.
Ringe JD; Farahmand P; Schacht E
Rheumatol Int; 2013 Mar; 33(3):637-43. PubMed ID: 22527138
[TBL] [Abstract][Full Text] [Related]
12. Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol.
Nakamura T; Takano T; Fukunaga M; Shiraki M; Matsumoto T
J Bone Miner Metab; 2013 Jul; 31(4):417-22. PubMed ID: 23575909
[TBL] [Abstract][Full Text] [Related]
13. Eldecalcitol: a review of its use in the treatment of osteoporosis.
Sanford M; McCormack PL
Drugs; 2011 Sep; 71(13):1755-70. PubMed ID: 21902297
[TBL] [Abstract][Full Text] [Related]
14. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
15. Eldecalcitol for the treatment of osteoporosis.
Matsumoto T; Endo I
Drugs Today (Barc); 2012 Mar; 48(3):189-96. PubMed ID: 22462038
[TBL] [Abstract][Full Text] [Related]
16. Potential of alfacalcidol for reducing increased risk of falls and fractures.
Ringe JD; Schacht E
Rheumatol Int; 2009 Aug; 29(10):1177-85. PubMed ID: 19159932
[TBL] [Abstract][Full Text] [Related]
17. [Frontiers in vitamin D; Basic research and clinical application. The effects of eldecalcitol on bone mineral density and fracture prevention--Post hoc analysis].
Hagino H
Clin Calcium; 2011 Nov; 21(11):111-8. PubMed ID: 22040827
[TBL] [Abstract][Full Text] [Related]
18. Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis.
Hagino H; Takano T; Fukunaga M; Shiraki M; Nakamura T; Matsumoto T
J Bone Miner Metab; 2013 Mar; 31(2):183-9. PubMed ID: 23129180
[TBL] [Abstract][Full Text] [Related]
19. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
20. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.
Ringe JD; Dorst A; Faber H; Schacht E; Rahlfs VW
Rheumatol Int; 2004 Mar; 24(2):63-70. PubMed ID: 14513268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
